1. India Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Biocon Limited

Biocon Limited

BIOCON.NS
Biocon LimitedIN flagNational Stock Exchange of India
403.60
INR
+6.55
- -
551.87BMarket Cap

Total Valuation

Biocon Limited carries a market capitalization of 551.87B, placing it among publicly traded companies globally. Its enterprise value stands at 626.66B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap551.87B
Enterprise Value626.66B

Share Statistics

Biocon Limited currently has 1.62B shares outstanding.

Shares Outstanding1.62B
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Biocon Limited trades at a trailing price-to-earnings ratio of 126.66. The price-to-sales ratio is 2.90, and the price-to-book ratio stands at 60.26.

PE Ratio126.66
PS Ratio2.90
PB Ratio60.26
P/TBV Ratio6.25
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Biocon Limited trades at an EV/EBITDA multiple of 42.30 and an EV/FCF ratio of 76.85. The EV/Sales ratio of 3.72 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 42.30 provides insight into valuation relative to core operating earnings.

EV / Sales3.72
EV / EBITDA42.30
EV / EBIT42.30
EV / FCF76.85

Financial Position

Biocon Limited maintains a current ratio of 1.22, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 42.14, indicating elevated leverage, while an interest coverage ratio of 1.50 demonstrates limited ability to service its debt obligations.

Current Ratio1.22
Quick Ratio0.30
Debt / Equity42.14
Debt / EBITDA10.42
Interest Coverage1.50

Financial Efficiency

Biocon Limited posts a return on equity of 3.79 and a return on invested capital of 2.47.

Return on Equity (ROE)3.79
Return on Assets (ROA)0.63
Return on Invested Capital (ROIC)2.47
Return on Capital Employed (ROCE)3.88
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.03

Taxes

Over the trailing twelve months, Biocon Limited has paid 791.00M in income taxes, reflecting an effective tax rate of 17.66.

Income Tax791.00M
Effective Tax Rate17.66

Stock Price Statistics

Biocon Limited's stock has gained approximately 8.04444% over the past 52 weeks. The 50-day moving average sits at 412.26, while the 200-day moving average is 385.60.

Beta (5Y)N/A
52-Week Price Change8.04444%
50-Day Moving Average412.26
200-Day Moving Average385.60
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Biocon Limited generated 168.30B in revenue and converted that into 3.86B in net income, yielding earnings per share of 2.71. EBITDA reached 14.81B, while operating income came in at 14.81B.

Revenue168.30B
Gross Profit30.85B
Operating Income14.81B
Pretax Income4.48B
Net Income3.86B
EBITDA14.81B
EBIT14.81B
Earnings Per Share (EPS)2.71

Balance Sheet

Biocon Limited holds 41.98B in cash and equivalents against 154.34B in total debt, resulting in a net debt position of 124.08B. Total book value stands at 8.11B, with working capital of 31.11B providing operational flexibility.

Cash & Cash Equivalents41.98B
Total Debt154.34B
Net Debt124.08B
Equity (Book Value)8.11B
Book Value Per Share5.99
Working Capital31.11B

Margins

Biocon Limited operates with a gross margin of 66.19, reflecting its pricing power and cost economics. The operating margin of 8.80 and net profit margin of 2.29 provide insight into operational efficiency.

Gross Margin66.19
Operating Margin8.80
Pretax Margin2.66
Profit Margin2.29
EBITDA Margin8.80

Stock Splits

Biocon Limited's most recent stock split took place on June 12, 2019 with a 1:2 split ratio.

Last Split Date6/12/2019
Split Ratio1:2

Scores

Biocon Limited posts an Altman Z-Score of 1.81, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.81